Activation of Retinoid X Receptor increases dopamine cell survival in models for Parkinson's disease. - Wikidata - awgldk - TriplyDB

Activation of Retinoid X Receptor increases dopamine cell survival in models for Parkinson's disease.

Activation of Retinoid X Receptor increases dopamine cell survival in models for Parkinson's disease.

http://www.wikidata.org/entity/Q33517934

about

The retinoid X receptors and their ligands Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease.Protein kinase D1 (PKD1) phosphorylation promotes dopaminergic neuronal survival during 6-OHDA-induced oxidative stress.Nurr1-Based Therapies for Parkinson's Disease.Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease.Ligand Dependent Switch from RXR Homo- to RXR-NURR1 Heterodimerization.Smoking and Parkinson disease: Evidence for gene-by-smoking interactions.

P2860

Q24562747-1C0D7212-2B64-43B0-A222-19BB1A948258 Q30557555-D3AAB85B-DE5B-46F0-807B-BA3C2F0DAB5E Q35164624-8AC1B7C2-3335-4105-84CA-CA5E7CE3FEA1 Q36803630-A9883A7F-5BE8-4DFD-B64D-EFAA8911EB02 Q36946543-FECD84B6-09CE-4137-AB3A-BD516D4E24C2 Q38686743-F7333FD9-794A-42C9-B557-F66248ED360F Q49911470-D1F28EA6-43BA-40B7-9843-41265626F96D

P2860

Activation of Retinoid X Receptor increases dopamine cell survival in models for Parkinson's disease.

http://www.wikidata.org/entity/Q33517934

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Activation of Retinoid X Recep ...... odels for Parkinson's disease.

@ast

Activation of Retinoid X Recep ...... odels for Parkinson's disease.

@en

Activation of Retinoid X Recep ...... odels for Parkinson's disease.

@nl

type

label

Activation of Retinoid X Recep ...... odels for Parkinson's disease.

@ast

Activation of Retinoid X Recep ...... odels for Parkinson's disease.

@en

Activation of Retinoid X Recep ...... odels for Parkinson's disease.

@nl

prefLabel

Activation of Retinoid X Recep ...... odels for Parkinson's disease.

@ast

Activation of Retinoid X Recep ...... odels for Parkinson's disease.

@en

Activation of Retinoid X Recep ...... odels for Parkinson's disease.

@nl

P1433

Q33517934-4F43CD88-EAE4-4691-92BD-051EB83325A2

P1476

Q33517934-814A4DF2-ED7F-4EDD-9644-14839F8C7E57

P2093

Q33517934-3D1D44F2-F970-4909-8AC7-84D00E1076A6

Q33517934-62DF9583-73B8-4974-AAE7-8428B94B1835

P2860

Q33517934-001485A8-5DCF-4CCF-8D42-9D47E7C25BAE

Q33517934-03FEEF15-69E0-48E8-AF96-A2AE6DD592C4

Q33517934-2042AB15-88BB-402B-BF39-39A83CD6289B

Q33517934-3674BBEB-68F3-4603-A6E6-20C9AEE40612

Q33517934-3B4DEE79-0BAD-4D7D-A20E-B7AE456FBAE2

Q33517934-44B8C427-6B6C-4094-B12F-08707E0FC7E1

Q33517934-499C3B5D-8CAE-4C20-8B50-1F12B099C057

Q33517934-4DB9AF89-6C20-4ECF-B295-07137F8DD67E

Q33517934-55AB9543-60A4-4411-AF2D-A615DDF5D4A8

Q33517934-604DB912-3F2D-457F-911A-2D4530F5C582

P2888

Q33517934-7A77BA7C-FD8D-4058-B4F8-D71E783B84AE

P304

Q33517934-46E4C707-C6A6-46F7-ABA8-CB2D29A9CB7D

P31

Q33517934-07DD4819-4E54-4580-9B1D-FCE3DC9088AA

P356

Q33517934-A024B629-BF79-4627-A7F5-F1F8C3AF670C

P478

Q33517934-05F21D42-43E4-42D4-8720-42F5AA4CE871

P50

Q33517934-379DE691-8EC3-4B8E-9493-4EA924204A3B

P577

Q33517934-4653E6CB-9B8E-432B-957E-4186E67D031C

P5875

Q33517934-7B46B793-A3A1-4F8F-9109-1D483532373B

P6179

Q33517934-6621727C-3A52-4EC9-BF7C-ECCE70DE5954

P698

Q33517934-E1EA0627-B6DA-43EC-8FBF-786FC0807790

P921

Q33517934-1f913272-5f71-4a21-ab93-b2357a447b67

Q33517934-FF782DD8-F199-4303-A106-8022D12BB109

P932

Q33517934-5D347937-8F6F-465E-A9AC-554D39D12E73

P356

1471-2202-10-146

P1433

BMC Neuroscience

P1476

Activation of Retinoid X Recep ...... odels for Parkinson's disease.

@en

P2093

Maria Bergsland

http://www.w3.org/2001/XMLSchema#string

Stina Friling

http://www.w3.org/2001/XMLSchema#string

P2860

Prospects for new restorative and neuroprotective treatments in Parkinson's disease

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor

Crossroads in GDNF therapy for Parkinson's disease

Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP+-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK

Nurr1 regulates dopamine synthesis and storage in MN9D dopamine cells

Dopamine neuron agenesis in Nurr1-deficient mice

Nurr1 enhances transcription of the human dopamine transporter gene through a novel mechanism.

Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease.

Defined conditions for neural commitment and differentiation.

P2888

1471-2202-10-146

P304

146

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2202-10-146

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Susanna Kjellander

P577

2009-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40681202

http://www.w3.org/2001/XMLSchema#string

P6179

1022550632

http://www.w3.org/2001/XMLSchema#string

P698

20003337

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

2800113

http://www.w3.org/2001/XMLSchema#string